Trial Profile
A phase I/II trial of MCLA-128
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 15 Jul 2016
Price :
$35
*
At a glance
- Drugs Zenocutuzumab (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Jul 2016 New trial record
- 12 Jul 2016 According to a Merus media release, the company expects to file an Investigational New Drug (IND) application with the US FDA for this trial by the end of 2016.